Rucaparib is a PARP inhibitor(a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase) used as an anti-cancer agent. Rucaparib camsylate is a white- pale yellow powder formulated into a tablet and is taken orally. Rucaparib tablets standard strength is 300 mg. Rucaparib is used to treat ovarian cancer and prostate cancer. It is approved for many other diseases too.
Dosage and administration
The inactive ingredients of Rucaparib are microcrystalline cellulose, sodium starch glycolate, colloidal silicon dioxide, and magnesium stearate. Before administering the Rucaparib tablets, the patients should consult the health care professional for proper dosage according to the patient's medical history. The General recommended dose of Rubraca is 600 mg (two 300 mg tablets) taken twice a day orally with or without food, a total daily dose of 1,200 mg. Continue dosage till no toxicity is experienced by the patients or progression is observed in the treatment of the disease. If the patient misses a dose of medicine, instruct the patient to take the next dose as scheduled. Do not replace the vomited dose.
Side Effects of Rucaparib
There are numerous side effects of the medicine Rucaparib. Common side effects are tiredness or weakness, nausea, vomiting, decreased hunger, dysgeusia, diarrhea, thrombocytopenia (low levels of platelets), and abdominal pain. Severe side effects are increased levels of creatinine (which may indicate kidney problems), liver enzymes in the blood (indication of liver problems), blood in urine, anemia (low red blood cell counts).
Precautions
Before administering, the patient should acknowledge the doctor about allergies or allergic reactions as Rucaparib 300 mg contains several inactive ingredients which may be allergic to the patient. Clinical advice is that females and males of reproductive potential should avoid becoming pregnant or planning to become pregnant while treating with Rucaparib because this medicine has potential risk to the fetus. Reproductive females and males should use effective contraception during treatment and 6 months after the last dose of the drug.
Myelodysplastic Syndrome (MDS) or Myeloid Leukemia (AML) occurs in patients treated with Rucaparib and has potentially fatal worsening effects. Do not start the medicine dosage until patients have recovered from hematological toxicity caused by previous chemotherapy or if the levels have not recovered to Grade 1 or less after 4 weeks. Or, if MDS/AML is suspected, refer the patient to a hematologist (a doctor who specializes in diagnosing, treating, and preventing blood-related problems and problems of the lymphatic system) for more medical examinations, including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue the treatment with Rucaparib.
Rucaparib cost and Availability
Rucaparib has no authority to be marketed in India yet. Still, Ikris Pharma Network can help the patients access this medicine under Named patient import programme.
Named patient is a programme under which an organization allows you to access the medication on a patient's name legally in your country.
